Rakuten Aspyrian is a privately funded clinical stage biotechnology company developing tumor-targeted precision therapies based on its proprietary platform Photoimmunotherapy. Photoimmunotherapy combines key advantages of antibody-mediated targeting of the cancer cells to achieve high tumor specificity, together with laser-activation of a biophysical mechanism that induces rapid cancer cell death with precision. Treatments with the Photoimmunotherapy platform lead to targeted and rapid tumor cell death by necrosis, with minimal effects on normal tissue. Rakuten Aspyrian is studying Photoimmunotherapy for use as a monotherapy and in combination with other drugs. Founded in 2013, the company is based in San Diego, California.
Some data provided by Crunchbase
EquityZen does not have an affiliation with, formal relationship with, or endorsement from Rakuten Aspyrian or any companies featured above.
This profile is based on publicly available information and is intended to be informative in nature.
To learn more about whether you're eligible, typical investment size, company valuation, and share price, request access here.